Ustekinumab improves health‐related quality of life in patients with moderate‐to‐severe Crohn's disease: STARDUST trial

https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/54/85/a4/5485a479-f7c3-4409-f01f-ce1aad1882d0/mza_13459005686379354626.jpg/600x600bb.jpg

UEG Journal

40 episodes

2 weeks ago

Podcast feed from the UEG Journal, the official journal from the United European Gastroenterology

Medicine

Health & Fitness

RSS

All content for UEG Journal is the property of UEG Journal and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Podcast feed from the UEG Journal, the official journal from the United European Gastroenterology

Medicine

Health & Fitness

https://images.podigee-cdn.net/0x,sWg4j5a4-G3RsU783VC2wdZUy-INjCzhcHXrMii_Jq0c=/https://main.podigee-cdn.net/uploads/u47126/27020302-74ae-463d-891d-7bf93fcc6258.jpg

Ustekinumab improves health‐related quality of life in patients with moderate‐to‐severe Crohn's disease: STARDUST trial

UEG Journal

9 minutes

2 years ago

Ustekinumab improves health‐related quality of life in patients with moderate‐to‐severe Crohn's disease: STARDUST trial

Dr. H. Tarik Kani talks to Dr. Axel Dignass (Germany) about his recent publication about the impact of Ustekinumab on health-related quality of life in moderate-to-severe Crohn’s disease which was an open-label, multicenter, randomized study evaluated the quality of life prospectively in Crohn’s patients who treated with Ustekinumab.